{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:19:32Z","timestamp":1791983972394,"version":"4.4.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1GM10880304"],"award-info":[{"award-number":["RO1GM10880304"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10 OD020012"],"award-info":[{"award-number":["S10 OD020012"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,20]]},"DOI":"10.1093\/nar\/gky1239","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T23:16:40Z","timestamp":1543533400000},"page":"1082-1096","source":"Crossref","is-referenced-by-count":211,"title":["Diverse lipid conjugates for functional extra-hepatic siRNA delivery\n                    <i>in vivo<\/i>"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9953-9265","authenticated-orcid":false,"given":"Annabelle","family":"Biscans","sequence":"first","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01604, USA"},{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3218-6957","authenticated-orcid":false,"given":"Andrew","family":"Coles","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01604, USA"},{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reka","family":"Haraszti","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01604, USA"},{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Echeverria","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01604, USA"},{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hassler","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01604, USA"},{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maire","family":"Osborn","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01604, USA"},{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-8071","authenticated-orcid":false,"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[{"name":"RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01604, USA"},{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"key\n\t\t\t\t2019021903334329000_B1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/ph6010085","article-title":"Nanoparticle-based delivery of RNAi therapeutics: progress and challenges","volume":"6","author":"Zhou","year":"2013","journal-title":"Pharmaceuticals"},{"key":"key\n\t\t\t\t2019021903334329000_B2","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-Acetylgalactosamine-Conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"JACS"},{"key":"key\n\t\t\t\t2019021903334329000_B3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","article-title":"Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate","volume":"25","author":"Zimmermann","year":"2017","journal-title":"Mol. Ther."},{"key":"key\n\t\t\t\t2019021903334329000_B4","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/nar\/gky037","article-title":"Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo","volume":"46","author":"Hassler","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"key\n\t\t\t\t2019021903334329000_B5","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.1093\/nar\/gkx818","article-title":"Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc\u2013siRNA conjugates","volume":"45","author":"Nair","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"key\n\t\t\t\t2019021903334329000_B6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"key\n\t\t\t\t2019021903334329000_B7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019021903334329000_B8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/jm049167j","article-title":"Fully 2\u2018-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA","volume":"48","author":"Allerson","year":"2005","journal-title":"J. Med. Chem."},{"key":"key\n\t\t\t\t2019021903334329000_B9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1261\/rna.1007408","article-title":"Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner","volume":"14","author":"Nallagatla","year":"2008","journal-title":"RNA"},{"key":"key\n\t\t\t\t2019021903334329000_B10","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1261\/rna.30706","article-title":"Position-specific chemical modification of siRNAs reduces \u201coff-target\u201d transcript silencing","volume":"12","author":"Jackson","year":"2006","journal-title":"RNA"},{"key":"key\n\t\t\t\t2019021903334329000_B11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"key\n\t\t\t\t2019021903334329000_B12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0300-9084(02)01459-1","article-title":"Developments in RNA chemistry, a personal view","volume":"84","author":"Eckstein","year":"2002","journal-title":"Biochimie"},{"key":"key\n\t\t\t\t2019021903334329000_B13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nature03514","article-title":"Structural basis for 5\u2032-end-specific recognition of guide RNA by the A. fulgidus Piwi protein","volume":"434","author":"Ma","year":"2005","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019021903334329000_B14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature09039","article-title":"Structural basis for 5\u2032-nucleotide base-specific recognition of guide RNA by human AGO2","volume":"465","author":"Frank","year":"2010","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019021903334329000_B15","doi-asserted-by":"crossref","first-page":"7581","DOI":"10.1093\/nar\/gkx507","article-title":"5\u2032-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo","volume":"45","author":"Haraszti","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"key\n\t\t\t\t2019021903334329000_B16","first-page":"987","article-title":"5\u2032-(E)-Vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA\u2013GalNAc conjugates","volume":"17","author":"Parmar","year":"2016","journal-title":"Chembiochem."},{"key":"key\n\t\t\t\t2019021903334329000_B17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbic.201500023","article-title":"Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-Acetylgalactosamine elicits robust gene silencing in vivo","volume":"16","author":"Rajeev","year":"2015","journal-title":"Chembiochem."},{"key":"key\n\t\t\t\t2019021903334329000_B18","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/cb501028c","article-title":"siRNA conjugates carrying sequentially assembled trivalent N-Acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes","volume":"10","author":"Matsuda","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"key\n\t\t\t\t2019021903334329000_B19","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"key\n\t\t\t\t2019021903334329000_B20","doi-asserted-by":"crossref","first-page":"12388","DOI":"10.1093\/nar\/gkx960","article-title":"Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes","volume":"45","author":"Tanowitz","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"key\n\t\t\t\t2019021903334329000_B21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"key\n\t\t\t\t2019021903334329000_B22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/nat.2018.0725","article-title":"Improving siRNA delivery In vivo through lipid conjugation","volume":"28","author":"Osborn","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"key\n\t\t\t\t2019021903334329000_B23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nbt1339","article-title":"Mechanisms and optimization of in vivo delivery of lipophilic siRNAs","volume":"25","author":"Wolfrum","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"key\n\t\t\t\t2019021903334329000_B24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/mt.2008.14","article-title":"Efficient in vivo delivery of siRNA to the liver by conjugation of \u03b1-tocopherol","volume":"16","author":"Nishina","year":"2008","journal-title":"Mol. Ther."},{"key":"key\n\t\t\t\t2019021903334329000_B25","doi-asserted-by":"crossref","first-page":"F605","DOI":"10.1152\/ajprenal.90268.2008","article-title":"Effects of cholesterol-tagged small interfering RNAs targeting 12\/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes","volume":"295","author":"Yuan","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"key\n\t\t\t\t2019021903334329000_B26","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1038\/mtna.2016.55","article-title":"Silencing myostatin using cholesterol-conjugated siRNAs induces muscle growth","volume":"5","author":"Khan","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"key\n\t\t\t\t2019021903334329000_B27","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.4297","article-title":"RNAi modulation of placental sFLT1 for the treatment of preeclampsia","author":"Turanov","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"key\n\t\t\t\t2019021903334329000_B28","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"PNAS"},{"key":"key\n\t\t\t\t2019021903334329000_B29","first-page":"1","article-title":"Transdermal delivery of siRNA through microneedle array","volume":"6","author":"Deng","year":"2016","journal-title":"Sci. Rep."},{"key":"key\n\t\t\t\t2019021903334329000_B30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.chom.2008.12.003","article-title":"Cell host & microbe article durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene","volume":"5","author":"Wu","year":"2009","journal-title":"Cell Host Microbe"},{"key":"key\n\t\t\t\t2019021903334329000_B31","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1038\/mtna.2015.38","article-title":"Hydrophobically modified siRNAs silence Huntingtin mRNA in primary neurons and mouse brain","volume":"4","author":"Alterman","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"key\n\t\t\t\t2019021903334329000_B32","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1038\/mtna.2016.50","article-title":"Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain","volume":"5","author":"Nikan","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"key\n\t\t\t\t2019021903334329000_B33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1021\/acs.bioconjchem.7b00226","article-title":"Synthesis and evaluation of parenchymal retention and efficacy of a metabolically stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA conjugate in mouse brain","volume":"28","author":"Nikan","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"key\n\t\t\t\t2019021903334329000_B34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/nat.2017.0690","article-title":"Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to Peptide Nucleic Acid hybridization assay","volume":"27","author":"Godinho","year":"2017","journal-title":"Nculeic Acid Ther."},{"key":"key\n\t\t\t\t2019021903334329000_B35","first-page":"1","article-title":"Oligonucleotide detection method","author":"Roehl","year":"2011","journal-title":"US Patent US20110201006A1"},{"key":"key\n\t\t\t\t2019021903334329000_B36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/nat.2015.0578","article-title":"A high-throughput method for direct detection of therapeutic oligonucleotide-induced gene silencing in vivo","volume":"26","author":"Coles","year":"2016","journal-title":"Nucleic Acid Ther."},{"key":"key\n\t\t\t\t2019021903334329000_B37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrm2330","article-title":"Membrane lipids: where they are and how they behave","volume":"9","author":"van\u00a0Meer","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"key\n\t\t\t\t2019021903334329000_B38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0022-2275(20)38891-X","article-title":"Composition of phospholipids and of phospholipid fatty acids of human plasma","volume":"8","author":"Phillips","year":"1967","journal-title":"J. Lipid Res."},{"key":"key\n\t\t\t\t2019021903334329000_B39","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/hep.20702","article-title":"Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication","volume":"41","author":"Morrissey","year":"2005","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019021903334329000_B40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/108729003321629638","article-title":"Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing","volume":"13","author":"Harbort","year":"2003","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"key\n\t\t\t\t2019021903334329000_B41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0022-2275(20)37381-8","article-title":"Reversed-phase high performance liquid chromatography of phosphatidylcholine: a simple method for determining relative hydrophobic interaction of various molecular species","volume":"22","author":"Smith","year":"1981","journal-title":"J. Lipid Res."},{"key":"key\n\t\t\t\t2019021903334329000_B42","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nbt936","article-title":"Rational siRNA design for RNA interference","volume":"22","author":"Reynolds","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"key\n\t\t\t\t2019021903334329000_B43","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ki.1995.406","article-title":"Renal uptake of an 18-mer phosphorothioate oligonucleotide","volume":"48","author":"Oberbauer","year":"1995","journal-title":"Kidney Int."},{"key":"key\n\t\t\t\t2019021903334329000_B44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"key\n\t\t\t\t2019021903334329000_B45","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.physbeh.2007.03.026","article-title":"Forty mouse strain survey of body composition","volume":"91","author":"Reed","year":"2007","journal-title":"Physiol. Behav."},{"key":"key\n\t\t\t\t2019021903334329000_B46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1523-1747.1999.00807.x","article-title":"Overgrowth of skin in growth hormone transgenic mice depends on the presence of male gonads","volume":"113","author":"Wanke","year":"1999","journal-title":"J. Investig. Dermatol."},{"key":"key\n\t\t\t\t2019021903334329000_B47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep15699","article-title":"Plasmodium berghei ANKA causes intestinal malaria associated with dysbiosis","volume":"5","author":"Taniguchi","year":"2015","journal-title":"Sci. Rep."},{"key":"key\n\t\t\t\t2019021903334329000_B48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"key\n\t\t\t\t2019021903334329000_B49","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"key\n\t\t\t\t2019021903334329000_B50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J. Control Release"},{"key":"key\n\t\t\t\t2019021903334329000_B51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/genes8030093","article-title":"Antisense oligonucleotides used to target the DUX4 mRNA as therapeutic approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)","volume":"8","author":"Ansseau","year":"2017","journal-title":"Genes"}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/47\/3\/1082\/27854133\/gky1239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T01:26:02Z","timestamp":1662513962000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/47\/3\/1082\/5245439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,14]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,12,14]]},"published-print":{"date-parts":[[2019,2,20]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gky1239","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/289439","asserted-by":"object"}]},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2,20]]},"published":{"date-parts":[[2018,12,14]]}}}